| Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2 M Ko, Y Huang, AM Jankowska, UJ Pape, M Tahiliani, HS Bandukwala, ... Nature 468 (7325), 839-843, 2010 | 1492 | 2010 |
| Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis H Makishima, V Visconte, H Sakaguchi, AM Jankowska, S Abu Kar, ... Blood, The Journal of the American Society of Hematology 119 (14), 3203-3210, 2012 | 480 | 2012 |
| Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms AM Jankowska, H Szpurka, RV Tiu, H Makishima, M Afable, J Huh, ... Blood, The Journal of the American Society of Hematology 113 (25), 6403-6410, 2009 | 456 | 2009 |
| Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A AM Jankowska, H Makishima, RV Tiu, H Szpurka, Y Huang, F Traina, ... Blood, The Journal of the American Society of Hematology 118 (14), 3932-3941, 2011 | 368 | 2011 |
| Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms F Traina, V Visconte, P Elson, A Tabarroki, AM Jankowska, E Hasrouni, ... Leukemia 28 (1), 78-87, 2014 | 361 | 2014 |
| Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation AE Schade, GL Schieven, R Townsend, AM Jankowska, V Susulic, ... Blood, The Journal of the American Society of Hematology 111 (3), 1366-1377, 2008 | 325 | 2008 |
| SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts V Visconte, H Makishima, A Jankowska, H Szpurka, F Traina, A Jerez, ... Leukemia 26 (3), 542-545, 2012 | 274 | 2012 |
| Novel homo-and hemizygous mutations in EZH2 in myeloid malignancies H Makishima, AM Jankowska, RV Tiu, H Szpurka, Y Sugimoto, Z Hu, ... Leukemia 24 (10), 1799-1804, 2010 | 221 | 2010 |
| SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes V Visconte, HJ Rogers, J Singh, J Barnard, M Bupathi, F Traina, ... Blood, The Journal of the American Society of Hematology 120 (16), 3173-3186, 2012 | 218 | 2012 |
| CBL, CBLB, TET2, ASXL1, and IDH1/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia H Makishima, AM Jankowska, MA McDevitt, C O'Keefe, S Dujardin, ... Blood, The Journal of the American Society of Hematology 117 (21), e198-e206, 2011 | 185 | 2011 |
| Multiple mechanisms deregulate EZH2 and histone H3 lysine 27 epigenetic changes in myeloid malignancies SN Khan, AM Jankowska, R Mahfouz, AJ Dunbar, Y Sugimoto, N Hosono, ... Leukemia 27 (6), 1301-1309, 2013 | 165 | 2013 |
| Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry RJP de Magalhães, MB Vidriales, B Paiva, C Fernandez-Gimenez, ... Haematologica 98 (1), 79, 2013 | 164 | 2013 |
| Loss of heterozygosity in 7q myeloid disorders: clinical associations and genomic pathogenesis A Jerez, Y Sugimoto, H Makishima, A Verma, AM Jankowska, ... Blood, The Journal of the American Society of Hematology 119 (25), 6109-6117, 2012 | 142 | 2012 |
| Phenotypic differences between healthy effector CTL and leukemic LGL cells support the notion of antigen-triggered clonal transformation in T-LGL leukemia MW Wlodarski, Z Nearman, A Jankowska, N Babel, J Powers, P Leahy, ... Journal of Leucocyte Biology 83 (3), 589-601, 2008 | 140 | 2008 |
| Increased CDA expression/activity in males contributes to decreased cytidine analog half-life and likely contributes to worse outcomes with 5-azacytidine or decitabine therapy RZ Mahfouz, A Jankowska, Q Ebrahem, X Gu, V Visconte, A Tabarroki, ... Clinical cancer research 19 (4), 938-948, 2013 | 138 | 2013 |
| Topography, clinical, and genomic correlates of 5q myeloid malignancies revisited A Jerez, LP Gondek, AM Jankowska, H Makishima, B Przychodzen, ... Journal of clinical oncology 30 (12), 1343, 2012 | 134 | 2012 |
| Mutations of an E3 ubiquitin ligase c-Cbl but not TET2 mutations are pathogenic in juvenile myelomonocytic leukemia H Muramatsu, H Makishima, AM Jankowska, H Cazzolli, C O'Keefe, ... Blood, The Journal of the American Society of Hematology 115 (10), 1969-1975, 2010 | 126 | 2010 |
| Single Nucleotide Polymorphism Array Lesions, TET2, DNMT3A, ASXL1 and CBL Mutations Are Present in Systemic Mastocytosis F Traina, V Visconte, AM Jankowska, H Makishima, CL O’Keefe, P Elson, ... Public Library of Science 7 (8), e43090, 2012 | 120 | 2012 |
| CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal hematopoietic precursors S Negrotto, KP Ng, AM Jankowska, J Bodo, B Gopalan, K Guinta, ... Leukemia 26 (2), 244-254, 2012 | 99 | 2012 |
| Complementation of hypersensitivity to DNA interstrand crosslinking agents demonstrates that XRCC2 is a Fanconi anaemia gene JY Park, EL Virts, A Jankowska, C Wiek, M Othman, SC Chakraborty, ... Journal of medical genetics 53 (10), 672-680, 2016 | 98 | 2016 |
Fabiola TrainaUniversity of CampinasDirección de correo verificada de unicamp.br
